The polycystic ovary syndrome (PCOS), one of the most common causes of hyperandrogenism and chronic oligo-anovulation, affects 4–7% of women [1]. The clinical features of PCOS are heterogeneous and may change throughout the lifespan, starting from adolescence to postmenopausal age. Among other factors, this is largely dependent on the influence of obesity and metabolic alterations, including an insulin resistant state and the metabolic syndrome, which consistently affect most women with PCOS [2].